GSK Reports Q1 2026 Financial Results Ahead of Expectations
GSK (GSK) reported better-than-expected Q1 2026 financial results, driven by strong sales in its HIV and cancer medicines, which offset a decline in general medicines, including respiratory therapies. The results were announced under new CEO Luke Miels.
Tickers: $GSK
Topics: CEO transition general medicines HIV and cancer medicines Q1 2026 financials respiratory therapies